Trump Psychedelics EO Fast-Track
Key Questions
What is the Trump Psychedelics EO Fast-Track?
President Donald Trump signed an executive order to accelerate FDA reviews of psychedelics like ibogaine, incorporating CNPVs. It also provides $50 million in HHS funding for states to support research and access. This signals mental health regulatory reform.
Who supports the psychedelics executive order?
The initiative is backed by RFK Jr. and veterans. It comes amid setbacks for Lykos Therapeutics. Their support highlights focus on mental health treatments.
What are the potential outcomes of this executive order?
It could lead to psychedelic treatment approvals as early as 2027. The order boosts research and expands access. This reflects broader reforms in mental health regulations.
EO accelerates FDA reviews of ibogaine/psychedelics w/ CNPVs and $50M HHS funding for states. RFK Jr./vets back amid Lykos setbacks. Signals mental health reg reform, potential 2027 approvals.